Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.
CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma
Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma
Data from the DREAMM 7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma
Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.
Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma
Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.